cjc 1295 acetate ipamorelin acetate CJC-1295 and Peptide Injection CJC-1295 No DAC + Ipamorelin

no completed modern RCT

Combination peptide therapy may be considered for adults who: Are experiencing symptoms of age-related growth hormone decline (typically over 30) Have confirmed low or declining IGF-1 levels on laboratory testing Struggle with poor recovery from exercise or physical stress Experience persistent low energy or disrupted sleep despite healthy habits Notice unfavorable changes in body composition despite consistent diet and activity Want to support healthy aging and longevity through evidence-based interventions Have no contraindications to peptide therapy (active malignancies, certain pituitary conditions) Proper medical evaluation including comprehensive lab work, symptom assessment, and health history review determines whether combination therapy is appropriate and helps establish baseline values for tracking progress

When administered subcutaneously or intravenously, sermorelin acts like GHRH and stimulates the pituitary gland to release more human growth hormone (HGH)

These can include enhanced muscle mass, further reduction in fat, improved skin elasticity, and better overall physical performance